Introduction
Doxycycline is a semi-synthetic bacteriostatic tetracycline and a broad-spectrum antibiotic against Gram-negative and Gram-positive aerobic and anaerobic bacteria, Rickettsiae, Chlamydiae, Mycoplasmas and some protozoa (Jha et al., 1989; Prats et al., 2005) . Pharmacokinetics properties of doxycycline is superior than older tetracycline; in terms of higher lipid solubility, complete absorption, better tissue distribution, longer elimination half-life and lower affinity for calcium (Riond and Riviere, 1990; Goren et al., 1998) . The in vitro antimicrobial activity of doxycycline is more effective than other tetracycline for the treatment for respiratory, urinary and gastrointestinal tract diseases (Croubles et al., 1998; Abd El-Aty et al., 2004) . The bioavailability and bioequivalence studies play an important role in determining therapeutic efficacy t o register the generic drug products according to the Food and Drug Administration (FDA) regulations (Chen et al., 2001) . Bioavailability is defined as the rate and extent to which an active drug ingredient is absorbed and becomes available at the site of drug of action (Martinez and R iviere, 1993) . In case of Bioequivalence it i s defined as statistically equivalent bioavailability between two products at the same molar dose of the therapeutic moiety under similar experimental conditions (Chen et al., 2001; Toutain and Bousquet-Melou, 2004) . The drug products are said to be bioequivalent if they are pharmaceutical equivalents or pharmaceutical alternatives and if their rate and extent of absorption do not show a significant differences statistically according to the FDA regulations (Chen et al., 2001) . The aim of this study was to evaluate bioequivalence of two different doxycycline powder formulations after oral administration of a single dose in chickens.
Materials and Methods
Drugs: Two commercial products of doxycycline hydrochloride (hyclate) were compared. Providox ® (doxycylcine hydrochloride powder (200 mg/g), Provimi Jordan, Amman, Jordan) and Doxyvet 0-50 S ® (doxycycline hydrochloride powder, (500 mg/g), V.M.D, Arendonk, Belgium) were used. Working doxycycline solutions of each product contained 10 mg/ml of distilled water.
Animals: Twenty four broiler chickens, 43-45 days old and weighing 1.7-2.1 kg, were used in this study. The animals were from Provimi Jordan research farm (Madaba, Jordan). The animals were monitored for 2 weeks for any apparent clinical signs before administration of drug. The chickens had free access to water and feed and the feed was free from antibacterial drugs. Each chicken was fasted the night before the experiment.
Experimental design:
The chickens were allocated into two e qual groups (12 chickens/group) in a parallel design. Chickens of groups 1 and 2 were given a single oral dose of Providox and Doxyvet0-50 S , respectively, ® ® at a dose level of 20 mg/kg body weight. This dose was based on the manufacturer's approved daily dose. The blood samples (1-1.5 ml) were drawn up to 10 times at distribution (Vd ), where Vd = dose/AUC ($); total The samples were centrifuged directly at 1000g for 5 body clearance (Cl ), where Cl = dose/AUC; elimination minutes and then the plasma was harvested and stored rate (K ) was determined by least-square regression at -20 C until analysis.
analysis of terminal log-linear portions of the plasma o Drug analysis: The plasma concentrations o f elimination half-life (t ), where t = 0.639/K ; the doxycycline were measured using HPLC method a s maximum concentration (C ) and the corresponding described previously (Axisa et al., 2000) . All the solvents peak time (t ) were determined by inspecting the used were of HPLC grade. The HPLC system consisted individual drug plasma concentration-time profiles. The of a pump (LC-20AD) with UV-vis detector (SPD-M20A), relative bioavailability (F) was calculated as (AUC solvent degasser (DGV-20A5) and Shimadzu LC-/AUC ) ×100. The bioequivalence of drug products solution software (Ver 6.12 SP4) (Shimadzu, Japan).
were evaluated by comparing the test and reference Chromatographic separation was performed using a products parameters; AUC and C values through the Purospher Star RP-18e (5 µm, 125 mm ×4.6 mm) 90% confidence intervals test were within the range 80 column (Merck, Germany) with an isocratic mobile to 125% according to Statistical analysis on the pharmacokinetics parameters a 0.45 µm membrane and degassed. The mobile phase of doxycycline products were assessed by analysis of was eluted at a flow rate of 1.5 ml/min and detected at variance (ANOVA). The differences were considered a UV wavelength of 347 nm. A standard calibration curve significant when p < 0.05. All data are expressed as was prepared by adding 200 µl of doxycycline (1 mg/ml mean ± SE. in water) to 800 µl of antibacterial-free chicken plasma. This was further diluted into antibacterial-free chicken plasma to produce solutions at concentrations of 0.1, 0.5, 1, 5 and 10 µg/ml. The peak areas were achieved by the measurement of peak area ratios using integration peak program (LC-solution software; Shimadzu, Japan). The standard curve of doxycycline in plasma which was linear at the doxycycline concentrations of 0.1 to 10 mg/ml (R =0.998). The limit of quantification for 2 doxycycline was 0.1 µg/ml.
Pharmacokinetics and statistical analysis:
The pharmacokinetics analysis of the data was performed using non-compartmental analysis based on the statistical moment theory (SMT) according to the method described by Gibaldi and Perrier (1982) , with the help of the WinNonLin noncompartmental analysis program (version, 5.2, Pharsight, USA). The calculated parameters were: Area under plasma concentrationtime curve (AUC) using linear trapezoid method; area 
Results
The plasma concentration-time profiles of two formulations were similar through the entire study periods (Table 1 and Fig. 1 ). Plasma doxycycline was detected at first sampling time (15 minutes) and gradually increased and reached a peak concentration (C ) of 5.36 ± 0.26 and 5.08 ± 0.25 µg/ml at 3.6 ± 0.22 max and 3.8 ± 0.26 h for Providox and Doxyvet0-50 S , ® ® respectively (Table 2 ). Doxycycline's concentrations declined below limits of quantification at 48 hours for both formulations. The average mean of AUC for Providox and Doxyvet0-50 S was 62.32 ± 3.34 and ® ® 57.55 ± 4.66 (µg.h)/ml, respectively (Table 2) . However, long elimination half-lives (t ) (13.93 ± 0.84 and 10.06
1/2$ ± 1.27 h), low total body clearance (Cl ) (0.23 ± 6.54 and # 0.26 ± 13.91 ml/min/kg) and high volume of distribution (Vd /F) (4.20 ± 0.27 and 3.60 ± 0.66 L/kg) were area determined for Providox and Doxyvet0-50 S , ® ® respectively (Table 2) . No significant differences were found among all the tested pharmacokinetics parameters. The relative bioavailability of Providox ® compared to Doxyvet0-50 S was 108.28 % (Table 3) . (Table 3) .
Discussion
The pharmacokinetics of doxycycline was reported in chickens following different routes of administrations (Anadon et al., 1994; Laczay et al., 2001; Ismail and ElKattan, 2004) . However, no studies are available on the pharmacokinetics comparisons and bioequivalence for different doxycycline powder formulations after oral administration in poultry. Therefore, the current study was designed to investigate pharmacokinetics and bioequivalence of doxycycline in broiler chickens of two powder formulations after oral administration. Doxycycline plasma concentrations were detected at first sampling (0.25 h) with a similar C (5.36 ± 0.52 and Anadon et al., 1994; Santos et al., 1996; Baert et a l., 2000; Laczay et al., 2001) . High volume o f distribution (4.20 ± 0.27 and 3.60 ± 0.66 L/kg) and a low total body clearance (0.23±6.54 and 0.26±13.91 ml/min/kg) for Providox and Doxyvet 0-50 S , ® ® respectively; indicates that doxycycline is rapidly absorbed, widely distributed and slowly eliminated in the body after oral administration in chickens as well as reported by Anadon et al. (1994) , Laczay et al. (2001) and Ismail and El-Kattan (2004) . Doxycycline peak plasma concentration for both formulations was higher than the minimum inhibitory concentrations (MICs) for Mycoplasma gallisepticum (0.2 µg/ml) (Takahashi and Yoshida, 1989) , Mycoplasma Pneumoniae (< 0.5 µg/ml) (Waites et al., 2003) , Staphylococcus aureus (0.25 µg/ml) (Bryant et al., 2000) , Streptococcus pneumoniae (< 0.4 µg/ml) (Aronson, 1980) and E. coli (1-4 µg/ml) (Moskowitz et al., 2004) . However, doxycycline peak plasma concentration for both formulations was lower than the MICs for Pseudomonas aeruginosa (>64 µg/ml) (Toutain and Bousquet-Melou, 2004) and Enterococcus fecalis (8 to 32 µg/ml) (Hoelscher et al., 2006) . This emerge the therapeutic usefulness of doxycycline i n control many susceptible bacteria. Bioequivalence study is a test to assure the clinical efficacy of a generic versus brand drugs (Chen et al., 2001) . Our results showed that the ratios of mean values of two doxycycline powder products were around 100 % (Table 3) in AUC and C and the 90% 0-24 max confidence intervals of both parameters for Providox ® were within the acceptable range (80-125%) (Table 3) when compared with the Doxyvet0-50 S. Both ® formulations were shown to be bioequivalent in terms of rate and extent of absorption. No significant differences were observed between the pharmacokinetics parameters of the two formulations, these results were showing the bioequivalence of the two formulations were according to the criteria established by FDA (Chen et al., 2001 ).
